Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics
Analyst John Newman of Canaccord Genuity maintained a Buy rating on Seres Therapeutics (MCRB – Research Report), retaining the price ...
bovnews2h
Seres Therapeutics Inc (MCRB) Stock: Beyond the Surface of Its Performance?
On Wednesday, Seres Therapeutics Inc (MCRB) stock saw a decline, ending the day at $0.59 which represents a decrease of $-0.07 or -10.61% from the prior close of $0.66. The stock opened at $0.65 and ...
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Thank you for standing by. My name is Bella, and I will be your ...
Seres Therapeutics Reports Q3 2024 Results and Strategic Progress
Seres Therapeutics Inc. ( (MCRB) ) has released its Q3 earnings. Here is a breakdown of the information Seres Therapeutics Inc. presented to ...
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
Seres Therapeutics Inc (MCRB) reports promising clinical results and strategic financial maneuvers, despite facing increased ...